RNA regulation, genetic medicine, and biotech research by CAMP4 Therapeutics
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy
Camp4 Therapeutics Corp participated in the fourth annual BioConnect Investor Conference hosted by H.C. Wainwright & Co., where CEO Josh Mandel-Brehm joined a fireside chat to present the ...
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston
Camp4 Therapeutics Corp announced it will present new preclinical data at the TIDESUSA conference in Boston. The company plans to showcase results demonstrating its lead candidate's ability to ...
Camp4 Therapeutics Corp targets capital discipline with new R and D focus
Camp4 Therapeutics Corp is sharpening its R and D strategy amid tighter capital conditions, according to remarks by CFO Kelly Gold. The company is placing greater emphasis on program ...
Camp4 Therapeutics Corp posts Q1 2026 financial results and reveals corporate developments
Camp4 Therapeutics Corp announced its financial results for the first quarter of 2026, along with key corporate updates. The company shared the news via a press release, accessible through its ...
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress
Camp4 Therapeutics Corp announced its participation in the SYNGAP1 Symposium hosted by CureSYNGAP1. The company’s Chief Medical Officer, Yuri Maricich, MD, and Chief Business and Operations ...
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes
Camp4 Therapeutics Corp organized a ski outing for its employees last month as part of a team-building initiative. The event gathered staff for recreational activities outside the workplace, ...
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity
Camp4 Therapeutics Corp has announced its sponsorship of the 10th Annual Impact Breakfast organized by CaresBoston. The event brings together members of the life sciences community to support ...
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships
Camp4 Therapeutics Corp is intensifying efforts to tackle the complexities of drug discovery by leveraging creative and resourceful strategies across diverse research partnerships. The company's ...
Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push
Camp4 Therapeutics Corp has announced the appointment of Michael MacLean to its Board of Directors. MacLean brings 35 years of expertise in financial and operational leadership to the company. ...
Camp4 Therapeutics Corp posts full year 2025 financial results and unveils corporate update
Camp4 Therapeutics Corp reported its full year 2025 financial results alongside key corporate developments. The company disclosed these updates through an official press release, signaling an ...
Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines
Camp4 Therapeutics Corp is set to present its latest research on regulatory RNAs aimed at increasing gene expression in haploinsufficiency diseases at the 2026 Cancer Epigenetics Institute ...
Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment
Camp4 Therapeutics Corp will present a novel method using antisense oligonucleotides (ASOs) to enhance gene expression and potentially treat diseases such as SYNGAP1 at the Keystone Symposium’s ...
Camp4 Therapeutics Corp commits to new therapies for rare and neurological diseases
Camp4 Therapeutics Corp has announced its commitment to advancing potential therapies targeting the underlying biology of rare and neurological diseases. The company highlighted the ongoing ...
Camp4 Therapeutics Corp engages with SYNGAP1 community in Poland family day event
Camp4 Therapeutics Corp executives, including Chief Medical Officer Yuri Maricich and Vice President and Head of Clinical Operations Biljana Bazdar- Vinovrski, participated in a SYNGAP1 Family Day ...
